Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 389 | 60 | 324 |
| Samples | 177 | 35 | 139 |
| Peptides | 133 | 25 | 110 |
Function
DUSP6 · Dual specificity phosphatase 6
The protein encoded by this gene is a member of the dual specificity protein phosphatase subfamily. These phosphatases inactivate their target kinases by dephosphorylating both the phosphoserine/threonine and phosphotyrosine residues. They negatively regulate members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), which are associated with cellular proliferation and differentiation. Different members of the family of dual specificity phosphatases show distinct substrate specificities for various MAP kinases, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli. This gene product inactivates ERK2, is expressed in a variety of tissues with the highest levels in heart and pancreas, and unlike most other members of this family, is localized in the cytoplasm. Mutations in this gene have been associated with congenital hypogonadotropic hypogonadism. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2014].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 122 amino-acid changes on canonical ENST00000279488 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DUSP6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DUSP6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 4/42 10% | 3/612 0% |
| Colorectal Carcinoma | 5/143 4% | 30/3239 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Melanoma | 9/210 4% | 10/1899 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 11/1592 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 8/1390 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Prostate Carcinoma | 0/13 0% | 10/2105 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Small Cell Lung Carcinoma | 2/9 22% | 1/752 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 6/2550 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 0/2534 0% |
| Other Blood Cancers | 2/61 3% | 0/2725 0% |
| Breast Carcinoma | 0/144 0% | 2/3264 0% |
Mutation Distribution
Where DUSP6 is mutated · all tissues, split by cell line vs tissue
How many mutations in DUSP6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 389 mutations in DUSP6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|